NEWTON, Mass. and GENEVA, Dec. 27, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. and its collaboration partner, RELIEF THERAPEUTICS Holding SA (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has approved…Original Article
FDA Approves Olpruva (sodium phenylbutyrate) for Patients with Urea Cycle Disorders
